Please leave this field empty
(800) 458-6223 info@curesearch.org
Select Page

A Novel Epigenetic Strategy to Treat Ewing Sarcoma


“Discovering new targeted treatments for metastatic Ewing sarcoma.”

What This Project Does

Mary Beckerle
  • Mary Beckerle, PhD
  • Ralph E. and Willia T. Main Presidential Professor
    CEO and Director, Huntsman Cancer Institute
    The University of Utah

A team at the University of Utah’s Huntsman Cancer Institute led by Mary Beckerle, PhD and including Steve Lessnick, MD, PhD, Sunil Sharma, MD, and Alana Welm, PhD has received a $1.73 million grant from CureSearch to test a novel targeted treatment for Ewing sarcoma that they hope will disrupt the growth and spread of the cancer.

Ewing sarcoma occurs because of a chromosomal abnormality that causes an atypical protein, known as EWS/FLI, to be expressed. When EWS/FLI is present, it causes literally thousands of genes mutate. In previous research, Dr. Beckerle’s team determined that EWS/FLI also disrupts the internal cellular skeleton, which compromises the ability of the cells to adhere (stick) and remain in their normal environment. A cell that cannot remain in its normal environment is more likely to travel to another area of the body, facilitating the spread of the tumor. Therefore, being able to stop EWS/FLI from changing a cell’s “stickiness” might help stop the spread of cancer.

Because it is difficult to directly inhibit EWS/FLI, Dr. Beckerle and her team are focused on a key regulator of EWS/FLI function, an enzyme called lysine specific demethylase (LSD1). Inhibitors of LSD1 thus represent a promising a new treatment approach for Ewing sarcoma. In their preliminary work, they used a computational chemistry approach to develop a molecule to inhibit (stop) LSD1. This agent displays potent anti-tumor activity when human Ewing sarcoma is implanted in mice. The LSD1 inhibitor reverses the effects of EWS/FLI and restores spreading and adhesion of the Ewing sarcoma cells, effects that the team proposes would prohibit the tumor cells from escaping and traveling to other areas of the body.

Now they will expand their discovery with the goal of moving this approach into the clinic as a targeted therapy for Ewing sarcoma. They will evaluate the treatment effects of LSD1 inhibition–alone or in combination with other medications in the form of preclinical trials. To do this, they will use a mouse model of metastatic Ewing sarcoma that mirrors the cancer in humans. At the same time, they will develop biomarkers and imaging tests to monitor responses to treatment and perform studies to assess the safety and toxicity of the new treatment, while determining appropriate dosing and timing which will serve as a guide when testing moves from the laboratory into patients.

To pursue these goals, a multidisciplinary scientific team at Huntsman Cancer Institute at the University of Utah has been assembled. Team members include: Dr. Mary Beckerle, a cell biologist who is a specialist in cell adhesion and motility and who serves as the Principal Investigator on the project; Dr. Steve Lessnick, pediatric oncologist with a long standing program in Ewing sarcoma research; Dr. Sunil Sharma, an oncologist with drug development and early phase clinical trial expertise in both the pharmaceutical and academic settings; Dr. Alana Welm a specialist in bone metastasis and development of predictive preclinical models; As well as collaborators, Drs. Lor Randall and Kevin Jones, surgical oncologists; Dr. Mary Bronner, pathologist; Dr. John Hoffman, molecular imaging specialist.

Potential Impact on Children

Ewing sarcoma is the second most common bone cancer in children and is a challenging cancer to treat because it has typically metastasized, or spread, by the time it is diagnosed. Treatment for Ewing sarcoma involves surgery and chemotherapy, but many children will relapse with metastatic disease. Those who do relapse have poor survival rates. Dr. Beckerle and her team want to change the outcome for children with metastatic Ewing sarcoma. If their work is successful, they will develop a new treatment that stops Ewing sarcoma from spreading and changes the odds for these high-risk children.

Project Updates

36 Month Research Update

Dr. Beckerle and her team at the Huntsman Cancer Institute have developed a novel treatment for metastatic Ewing sarcoma that targets an enzyme called LSD1. The work has lead to the discovery of a new class of inhibitors for LSD1. They have shown that the drug, SP-2577, prevents the spread of Ewing sarcoma in animal models.

In the past year, they completed all necessary preclinical testing as well as completed key steps in developing the drug for clinical application. They carried out extensive safety and toxicity testing which show the drug to be ready for clinical testing. The team is excited to report they are approaching a key milestone – the launching of a pediatric clinical trial. They will submit an investigational new drug (IND) application to the FDA in January 2017 to gain approval for a pediatric clinical trial for Ewing sarcoma in children age 12 and above.

As a positive step, the team obtained compassionate use approval from the FDA for testing in a single patient. The patient was treated for a total of 12 weeks with increasing doses of SP-2577 every week. The patient showed a clinical benefit from the treatment and the progression of the disease stabilized with minimal side effects. The patient went off the study after 12 weeks to pursue other therapies. The implications of this single study are promising and show that the drug may be safe for use in young patients. The outcome of this study is extremely encouraging. It improved the patient’s condition to a point where they can be treated with more standard therapies, with a far more favorable outcome.

Given the tremendous unmet medical need for treating Ewing sarcoma, it gives great hope that SP-2577 will be effective for future patients. In Dr. Beckerle’s words: “The strong direction of CureSearch leadership reminded us that the most important thing was progress toward the clinic, not academic publications. CureSearch provided exactly the kind of support and encouragement that enabled us to shift to team science, with clarity of purpose and the goal of advancing our science to the clinic.”

Acknowledgments

This program is supported in part by generous contributions from the Nick Currey Fund. For more information about the Nick Currey Fund, visit www.curesearch.org/Nick-Currey-Fund.

A Novel Epigenetic Strategy to Treat Ewing Sarcoma was last modified: March 13th, 2017 by Geoff Duncan

Pin It on Pinterest

Menu